The Lancet· Domenica Lorusso, Jérôme Martin-Babau, Floor Backes, Maria Pilar Barretina Ginesta, Jacob Korach, Shibani Nicum, Julian Wampfler, Jianqing Zhu, Monika Ducceschi, Toon Van Gorp, Magnus Frödin-Bolling, Flora Zagouri, Judith R Kroep, Isabelle Ray-Coquard, Vanda Salutari, Michelle D S Lightfoot, Todd Tillmanns, David M O’Malley, Kosei Hasegawa, Jung-Yun Lee, Gonzalo H Giornelli, Vanessa Samouëlian, Yoland Antill, Jundong Li, Shin Nishio, Jack Junjie Chan, Bradley J Monk, Chenxiang Li, Kristina Woodhouse, Robert Orlowski, Carmen García-Duran, Bhavana Pothuri, TroFuse-005/ENGOT-en23/GOG-3095 Investigators·· 4 hours agoScore77
[Articles] Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
In brief
Sacituzumab tirumotecan significantly improved progression-free survival and overall survival versus treatment of physician's choice in patients with advanced or recurrent endometrial cancer. The randomised, open-label, phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial enrolled patients who had received platinum-based chemotherapy and immunotherapy, and the findings support sacituzumab tirumotecan as a new standard of care for these patients.
Source: The Lancet · thelancet.com